Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma

被引：42

作者：

Robert, C. ^{[1
]}

Karaszewska, B. ^{[2
]}

Schachter, J. ^{[3
]}

Rutkowski, P. ^{[4
,5
]}

Mackiewicz, A. ^{[6
]}

Stroyakovskiy, D. ^{[7
]}

Lichinitser, M. ^{[8
]}

Dummer, R. ^{[9
]}

Grange, F. ^{[10
]}

Mortier, L. ^{[11
]}

Chiarion-Sileni, V. ^{[12
]}

Drucis, K. ^{[13
]}

Krajsova, I. ^{[14
]}

Hauschild, A. ^{[15
]}

Mookerjee, B. ^{[16
]}

Legos, J. ^{[16
]}

Schadendorf, D. ^{[17
]}

机构：

[1] Gustave Roussy, CH-8091 Villejuif Paris, France

[2] Przychodnia Lekarska Komed, Konin, Poland

[3] Chaim Sheba Med Ctr, Ramat Gan, Israel

[4] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[5] Inst Oncol, Warsaw, Poland

[6] Poznan Univ Med Sci, Poznan, Poland

[7] Moscow City Oncol Hosp 62, Moscow, Russia

[8] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[9] Univ Zurich Hosp, Zurich, Switzerland

[10] Ctr Hosp Univ Robert Debre, Reims, France

[11] Univ Lille 2, CHRU Lille, Lille, France

[12] Veneto Oncol Inst, Padua, Italy

[13] Med Univ, Swissmed Ctr Zdrowia SA, Gdansk, Poland

[14] VFN 1LF UK Praha, Prague, Czech Republic

[15] Univ Hosp Schleswig Holstein, Kiel, Germany

[16] GlaxoSmithKline, Collegeville, PA USA

[17] Univ Hosp Essen, Essen, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31820-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3301

引用

页码：S663 / S664

页数：3

共 35 条

[21] Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.
Dummer, Reinhard
Long, Georgina V.
Tawbi, Hussein A.
Flaherty, Keith
Ascierto, Paolo Antonio
Nathan, Paul D.
Rutkowski, Piotr
Leonov, Oleg
Mandala, Mario
Lorigan, Paul
Ferrucci, Pier Francesco
Grob, Jean-Jacques
Meyer, Nicolas
Gogas, Helen
Stroyakovskiy, Daniil
Arance, Ana Maria
Pakhle, Neha
Waters, Sorcha
Ribas, Antoni
Schadendorf, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[22] A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600-mutant melanoma (COMBI-i)
Gasal, E.
Arance Fernandez, A. M.
Ascierto, P. A.
Atkinson, V.
Dummer, R.
Flaherty, K. T.
Grob, J-J.
Hansson, J.
Hassel, J.
Larkin, J.
Lebbe, C.
Long, G. V.
Lorigan, P.
Miller, W.
Nathan, P.
Ribas, A.
Robert, C.
Schadendorf, D.
Tawbi, H.
Upalawanna, A.
ANNALS OF ONCOLOGY, 2017, 28
[23] COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
Schadendorf, Dirk
Dummer, Reinhard
Flaherty, Keith T.
Robert, Caroline
Arance, Ana
de Groot, Jan Willem B.
Garbe, Claus
Gogas, Helen J.
Gutzmer, Ralf
Krajsova, Ivana
Liszkay, Gabriella
Loquai, Carmen
Mandala, Mario
Yamazaki, Naoya
Queirolo, Paola
Guenzel, Carolin
Polli, Anna
Thakur, Mahgull
di Pietro, Alessandra
Ascierto, Paolo A.
EUROPEAN JOURNAL OF CANCER, 2024, 204
[24] BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).
Kirkwood, John M.
Long, Georgina V.
Trefzer, Uwe
Davies, Michael A.
Ascierto, Paolo Antonio
Chapman, Paul B.
Puzanov, Igor
Hauschild, Axel
Robert, Caroline
Kefford, Richard
Goodman, Vicki L.
Switzky, Julie C.
Swann, R. Suzanne
Martin, Anne-Marie
Guckert, Mary E.
Streit, Michael R. W.
Schadendorf, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[25] Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
Bendell, Johanna C.
Atreya, Chloe Evelyn
Andre, Thierry
Tabernero, Josep
Gordon, Michael S.
Bernards, Rene
Van Cutsem, Eric
Tejpar, Sabine
Sidhu, Roger
Go, William Y.
Allred, Alicia
Motwani, Monica
Suttle, Benjamin B.
Wu, Yuehui
Hoos, Axel
Orford, Keith W.
Corcoran, Ryan Bruce
Schellens, Jan H. M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[26] An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
Dutriaux, Caroline
Robert, Caroline
Grob, Jean-Jacques
Mortier, Laurent
Dereure, Olivier
Lebbe, Celeste
Mansard, Sandrine
Grange, Florent
Neidhardt, Eve-Marie
Lesimple, Thierry
Machet, Laurent
Bedane, Christophe
Maillard, Herve
Dalac-Rat, Sophie
Nardin, Charlee
Szenik, Alexandra
Denden, Amine
Saiag, Philippe
EUROPEAN JOURNAL OF CANCER, 2022, 175 : 254 - 262
[27] Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial
Nathan, P.
Grob, J. J.
Dummer, R.
Ascierto, P. A.
Ribas, A.
Robert, C.
Schadendorf, D.
Flaherty, K. T.
Tawbi, H. A.
Hauschild, A.
Mandala, M.
Shah, R.
Banerjee, H.
Sarkar, R. P.
Lau, M. R.
Long, G. V.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S921 - S922
[28] Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
Planchard, David
Groen, Harry J. M.
Kim, Tae Min
Rigas, James R.
Souquet, Pierre Jean
Baik, Christina S.
Barlesi, Fabrice
Mazieres, Julien
Quoix, Elisabeth A.
Curtis, C. Martin
Mookerjee, Bijoyesh
Bartlett-Pandite, Arundathy N.
Tucker, Christine
D'Amelio, Anthony
Johnson, Bruce E.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[29] Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.
Chapman, Paul B.
Hauschild, Axel
Robert, Caroline
Larkin, James M. G.
Haanen, John B. A. G.
Ribas, Antoni
Hogg, David
Hamid, Omid
Ascierto, Paolo Antonio
Testori, Alessandro
Lorigan, Paul
Dummer, Reinhard
Sosman, Jeffrey Alan
Garbe, Claus
Maio, Michele
Nolop, Keith B.
Nelson, Betty J.
Joe, Andrew K.
Flaherty, Keith T.
McArthur, Grant A.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[30] An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928).
Planchard, David
Besse, Benjamin
Groen, Harry J. M.
Souquet, Pierre Jean
Quoi, Elisabeth A.
Baik, Christina S.
Barlesi, Fabrice
Kim, Tae Min
Mazieres, Julien
Novello, Silvia
Rigas, James R.
Upalawanna, Allison
D'amelio, Anthony Michael
Zhang, Pingkuan
Mookerjee, Bijoyesh
Johnson, Bruce E.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 →